Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Nature medicine | 10 Sep 2014
DA Stanley, AN Honko, C Asiedu, JC Trefry, AW Lau-Kilby, JC Johnson, L Hensley, V Ammendola, A Abbate, F Grazioli, KE Foulds, C Cheng, L Wang, MM Donaldson, S Colloca, A Folgori, M Roederer, GJ Nabel, J Mascola, A Nicosia, R Cortese, RA Koup and NJ Sullivan
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.
* Data courtesy of Altmetric.com